Related Experiment Videos
Myasthenia gravis in children: long-term follow-up
Insights
Juvenile myasthenia gravis patients experienced spontaneous remission, but thymectomy significantly increased remission rates, especially with early surgery. Factors like symptom presentation and co-occurring immune diseases influenced outcomes.
Area of Science:
- Neurology
- Immunology
- Pediatric Medicine
Background:
- Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder affecting neuromuscular transmission.
- Long-term outcomes and remission predictors in JMG remain incompletely understood.
- Congenital myasthenia gravis (CMG) represents a distinct genetic etiology.
Purpose of the Study:
- To analyze long-term observational data for patients with juvenile myasthenia gravis.
- To determine spontaneous and post-thymectomy remission rates in JMG.
- To identify factors associated with increased remission rates following thymectomy.
Main Methods:
- Retrospective analysis of 149 JMG patients with a median follow-up of 17 years (minimum 4 years).
- Eight CMG patients were studied separately.
- Assessment of spontaneous remission rates and remission rates after thymectomy, with analysis of associated clinical factors.
Main Results:
- A spontaneous remission rate of 22.4 per 1,000 person-years was observed in JMG.
- Thymectomy yielded higher remission rates: 260 per 1,000 person-years in the first year post-surgery, and 95 per 1,000 person-years in the subsequent two years.
- Early surgery, bulbar symptoms, absence of ocular/generalized symptoms, symptom onset between ages 12-16, and co-existing immune diseases predicted better postoperative remission.
Conclusions:
- Thymectomy significantly enhances remission rates in juvenile myasthenia gravis.
- Specific clinical characteristics and early surgical intervention are associated with improved outcomes.
- Associated non-immune (epilepsy, neoplasia) and immune (rheumatoid arthritis, diabetes, asthma, thyroid disease) disorders are noted in the JMG cohort.
Abstract:
We report observations made on 149 patients with juvenile myasthenia gravis studied from onset of disease for as long as 40 years. Median follow-up was 17 years; minimum was 4 years. Eight other patients with congenital myasthenia gravis were studied separately. Of the juvenile myasthenic patients, 85 (57%) underwent thymectomy because of diseases severity. In juvenile myasthenia gravis, a spontaneous remission rate of 22.4 per 1,000 person-years was observed, regardless of disease duration. A remission rate of 260 per 1,000 person-years was seen during the first year after thymectomy, with a rate of 95 per 1,000 person-years during the next 2 years. Early surgery, presence of bulbar symptoms, absence of ocular signs or generalized symptoms, onset of symptoms between ages 12 and 16, and presence of other immune disease were associated with increased postoperative remission rates. Epilepsy (4 patients) and neoplasia (7 patients) were the most frequent associated nonimmune disorders; rheumatoid arthritis (5 patients), juvenile-onset diabetes mellitus (3 patients), asthma (3 patients), and thyroid disease (3 patients) were the most frequent associated immune diseases.